Innovent's Groundbreaking Phase 3 Study Shows Promise for SYCUME® in Treating Inactive Thyroid Eye Disease #China #Suzhou #Innovent_Biologics #Thyroid_Eye_Disease #SYCUME®

Innovent's Groundbreaking Phase 3 Study Shows Promise for SYCUME® in Treating Inactive Thyroid Eye Disease #China #Suzhou #Innovent_Biologics #Thyroid_Eye_Disease #SYCUME®
Innovent Expands Global Phase 3 Study in Immunotherapy-Resistant NSCLC to Include Non-Squamous Patients #China #Suzhou #Innovent_Biologics #IBI363 #TAK-928
Innovent Unveils Cutting-edge Clinical Data on Oncology Pipeline at 2026 ESMO Annual Meeting #China #Suzhou #Innovent_Biologics #oncology_pipeline #ESMO_2026